SGLT-2 inhibitors provide morbidity and mortality benefits for patients with heart failure
1. SGLT-2 inhibitors reduced time to first hospitalization and cardiovascular death among patients with preserved, mildly reduced, and reduced ejection ...
Tag: Sotagliflozin
Sotagliflozin increase days-alive-and-out-of-hospital in patients with diabetes and heart failure
1. Sotagliflozin treatment was shown to increase the days-alive-and-out-of-hospital compared to placebo in patients with type 2 diabetes and heart ...
Sotagliflozin reduces hospitalizations and urgent visits for patients with diabetes and worsening heart failure
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...
Sotagliflozin reduces cardiovascular risk for patients with diabetes and worsening heart failure
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...